CARTHERai™
CAnceR THErapy Rating Algorithm Infrastructure
Technology
Powered by advanced Artificial Intelligence
The CARTHERai™ is a platform ranking cancer therapies based on “Biomarker Signatures” detected in an individual tumor.
It is an infrastructure of algorithms, first extracting all biomarkers from tumor data and then comparing them to “Biomarker Signatures” characterizing responders for each cancer therapy.
Learn more
Pawel Zawadzki, Chief Executive Officer
MutationsNoMore (MNM) was born when I painfully realized that cancer treatment selection is guided by only a fraction of available genomic data, in best-case scenario.
I understood that if one can learn how to interpret all changes defining an individual tumor and translate that information into clinical data, then these Mutations are No More harmful – quite the opposite: they can be used against cancer.
This is exactly what we create at MNM – a platform which interprets all tumor mutations (100% of the genome) and directly translates it into clinics, in a form of decision-making algorithm. That requires bridging biology/medicine/genomics/machine learning/human passion – something which our interdisciplinary team is exceptional at!
Pipeline
1. Multi-Omics DATA INTEGRATION (genomics, transcriptomics and proteomics) in a AI-driven workflow.
2. DATA PROCESSING to produce multi-level, high-throughput and robust MultiOmics database.
3. BIOMARKER EXTRACTION FROM A COHORT OF RESPONDERS – Extraction and testing of Multi-Omics’ biomarkers associated with specific tumors and patient responses to various anti-cancer therapies.
4. BIOMARKER BUNDLING – Our platform identifies the optimal combinations of biomarker interdependencies and builds AI-powered tools to predict clinical outcomes and understand tumor physiology.
5. TESTING AND VALIDATION of the model in a clinical learning environment.
Learn more
Our publications
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
The First Report of Biallelic Missense Mutations in the SFRP4 Gene Causing Pyle Disease in Two Siblings
A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection
